GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

narlumosbart   Click here for help

GtoPdb Ligand ID: 13084

Synonyms: Jinlitai® | JMT-103 | JMT103
Approved drug
narlumosbart is an approved drug (China (2023))
Compound class: Antibody
Comment: Narlumosbart (JMT103) is a fully human IgG4κ anti-RANKL (receptor activator of nuclear factor kappa-Β ligand) monoclonal antibody. It blocks the RANK/RANKL protein-protein interaction and thereby reduces pathological osteoclastogenesis in bone cancer.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
RANK ligand Hs Antibody Binding - - -
⤷